Form 4 for AIM AIM ImmunoTech Inc.
Accepted 2026-09-18 08:30:23 ET · period of report 2026-09-17 · accession 0001493152-26-043246 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-09-18 08:30 | 2026-09-17 | AIM | Equels Thomas K | CEO, Pres, Dir | P - Purchase | $0.208 | +24.0K | 126.8K | +23% | +$4,992 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-09-17 | P | A | 24,000 | $0.208 | 126,822 | D | — | — |